ProCE Banner Activity

CE / CME

Evolving Therapeutic Options in Aggressive B-Cell Lymphomas: Expert Guidance for the Community Multidisciplinary Team

Video

This webcast includes commentary from expert faculty regarding how therapeutic options for aggressive B-cell lymphoma are constantly evolving and how this affects the multidisciplinary team.

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: February 28, 2024

Expiration: February 27, 2025

Share

Faculty

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Incyte Corporation.

AstraZeneca

Incyte Corporation

Target Audience

This educational program is intended for medical oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who treat patients with aggressive B cell lymphomas.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of healthcare professionals to individualize the therapeutic management of patients with LBCL, DLBCL, and MCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement expert-recommended predictive and prognostic molecular profiling for appropriate patients with aggressive B-cell lymphoma subtypes to help guide treatment decisions

  • Select therapeutic regimens for patients with LBCL, DLBCL, or MCL based on available clinical data, line of treatment, disease characteristics, and patient goals and preferences to optimize clinical outcomes

  • Identify patients with aggressive B-cell lymphomas who are eligible for and likely to benefit from enrollment in a clinical trial

  • Integrate optimal supportive care strategies to manage adverse events associated with novel treatment regimens for aggressive B-cell lymphoma

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

John N. Allan, MD: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Genentech, Janssen, Lava, Lilly, Pharmacyclics; researcher: BeiGene, Genentech.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose, except ​Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.​

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daichii Sankyo, Lilly, Morphosys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 28, 2024, through February 27, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-068-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.